Cynosure Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Cynosure Group’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-32,067	Closed	-$399K	–	186
2026 Q1	$399K	Buy	+32,067	New	+$431K	0.05%	149

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Cynosure Group's AMRX Position: Q2 2026 in Review

Cynosure Group sold out of Amneal Pharmaceuticals (AMRX) in Q2 2026, closing a stake of 32,067 shares — an estimated $399K sold.

Cynosure Group first reported a position in AMRX in Q1 2026 and held it in 1 quarter. The position peaked at $399K in Q1 2026. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Cynosure Group reported no remaining Amneal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Cynosure Group sold 32,067 Amneal Pharmaceuticals shares in Q2 2026, an estimated $399K.
Cynosure Group first reported a position in Amneal Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Cynosure Group's Amneal Pharmaceuticals position peaked at $399K in Q1 2026.
310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Cynosure Group's 13F filing for Q2 2026, filed 5 Aug 2026.